Pontus Klein
Chief Development Officer Inverna Therapeutics
Seminars
Thursday 23rd April 2026
Precision RNA Splicing Through Targeted Pseudo-Exon Activation: A Novel Platform Unlocking Broad Therapeutic Potential
11:30 am
- A novel RNA splicing modulation platform that selectively activates pseudo-exons to precisely control gene and protein expression at the source of disease
- Targeted oligonucleotides function as an innovative molecular switch, displacing repressive RNA-binding proteins to enable pseudo-exon inclusion during splicing, deliberately altering mRNA and downstream protein production
- Powered by a proprietary map spanning over 90% of spliced protein-coding genes with pseudo-exons, the platform unlocks a vast therapeutic targeting space with broad applicability across many conditions
Wednesday 22nd April 2026
Panel Discussion: Differentiating Next-Gen Oligonucleotides for CNS Therapeutics Safety, Stability & Competitive Advantage
8:30 am
- Discussing safety profiles, stability and translational outcomes across different oligo subtypes including ASO’s, siRNA, saRNA, aptamers and more
- Comparative safety and toxicity considerations across subtypes including off target effects, immunogenicity and long-term durability
- Industry perspective on room for innovation and strategies to stand out in a crowded therapeutic landscape
- What differentiates next-generation modalities and how biopharma can differentiate themselves in an increasingly competitive space
